Vijay Kumar: Understood. Matt, maybe one for you. And I saw the Arvis 2.0 within the presentation. Where are we on in terms of adoption of Arvis? Are we at an inflection point? And what does 2.0 do, which is different from 1.0?
Matthew Trerotola: Yes, so 2.0 in the me was, after putting it out in the controlled launch, getting a lot of feedback, we went and made a number of improvements to the software and the hardware that were making it kind of easier to use in many ways, but also making it really very seamless with our empower instrument sets as well. And so the 2.0 was then kind of more of a full launch of Arvis, but we definitely decided to do it in a step-by-step way just to make sure that given that it’s a brand new to the world technology, let’s get 15 20 docs using it, get some good feedback, help them to ramp up, and then use what we learn there to make sure that as we go to a broader set of doctors, one, we’ve got great value proposition in terms of being able to help them understand how it’s going to be valuable, but also we’ve got the ability to help them to ramp fast and effectively with it.
And so that’s what the 2.0 launch was, and we’re right on track with that in terms of, as I said, a couple dozen surgeons using Arvis, some using it very heavily, some less heavily. The ones are using less heavily were learning why and how do we ramp them up in terms of how heavily they use it. And there’s some good learnings there, both about how to ramp surgeons fast, but also about which surgeons to target more as we do the broader launch. And then we’ve now got plenty of inventory on hand, ready to do a broader role as we work through this year. A lot of excitement in the field around the ability to bring Arvis to a broader set of knee surgeons, Hip & Knee surgeons, but particularly for the knee at this point, as we work through this year.
So we would expect that number to expand and be a good facilitator to our knee conversion efforts, but also start to generate a small but growing and high profit, recurring revenue stream on the knee front. On the shoulder front, as I said, it’s just an initial launch. So think of shoulder in the second half of this year being kind of where our knee was a year or so ago in terms of getting that first launch into the marketplace in the second half of this year and getting some good feedback that allows us to keep revenue and improving the product. We’ve been focused on making sure that by 2025, we are right there in the market with a very strong shoulder service offering to continue to be a strong leader there and shoulder with technology, as we always have been.
And we’re right on track for that with this announcement about the shoulder clearance for Arvis that just recently happened.
Vijay Kumar: Understood. Thanks, guys.
Kyle Rose: Thank you Operator. Next question.
Operator: Thank you. We conclude our question-and-answer session now, and with that, I would like to turn the conference back over to Matthew Trerotola for any closing remarks. Please go ahead.
Matthew Trerotola: Thank you for joining us this morning. I want to end the call by thanking our team members for a strong start to the year. We have a lot of momentum and excitement across the organization and remain committed to delivering value for our internal and external stakeholders. Thank you for listening in today and we look forward to sharing our second quarter results with you in early August.
Operator: And this concludes the conference. Thank you very much for attending todays presentation. You may now disconnect, have a great great day.
